For Immediate Release | November 1, 2023 |
Sumitomo Chemical Announces Revisions to Its Financial Forecast
for the Full Year Ending March 31, 2024
Based on recent performance trends, Sumitomo Chemical co., Ltd. has made revisions to its consolidated financial forecast for the full year ending March 31, 2024, previously announced on May 15, 2023, as detailed below.
Revisions to Consolidated Financial Forecast for the Full Year Ending March 31, 2024
(Millions of yen)
Sales | Core | Operating | Net Income | Earnings | |||
Operating | Attributable to | ||||||
Revenue | Income | Owners of the | per Share | ||||
Income * | (yen) | ||||||
Parent | |||||||
Previous forecast (A) | 2,900,000 | 40,000 | 20,000 | 10,000 | 6.12 | ||
Revised forecast (B) | 2,700,000 | -70,000 | -125,000 | -95,000 | -58.09 | ||
Variance in amount (B-A) | -200,000 | -110,000 | -145,000 | -105,000 | |||
Variance in percentage (%) | -6.9% | - | - | - | |||
Results for the full year | 2,895,283 | 92,752 | -30,984 | 6,987 | 4.27 | ||
ended March 31, 2023 | |||||||
- Core Operating Income is a gain and loss concept, reflecting recurring earning capacity, and deducts gains and losses incurred by non-recurring factors from operating income. It includes the share of profit from investments accounted for using the equity method.
Reasons for the Revision
Regarding the consolidated financial forecast for the full year ending March 31, 2024, sales revenue and core operating income are expected to be lower than the previous forecast. The revision is due to a decrease in demand and a deterioration in margins caused by the global economic downturn in Essential Chemicals & Plastics and Energy & Functional Materials. In addition, a liquidation of crop protection products inventory in the midst of weaker demand in South America and a deterioration of methionine business in Health & Crop Sciences also have affected the forecast.
Operating income and net income attributable to owners of the parent are also expected to fall short of the previous forecast due to the decrease in core operating income as well as the impact of the impairment loss posted in the half-year ended September 30, 2023.
Regarding future plans for improving Sumitomo Chemical's financial performance, please refer to the presentation materials for "Investors' Meeting for FY2023 1st Half Financial Results, Management Priorities and Business Strategies," which is scheduled to be held today.
Cautionary Statement
Statements made in this document with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties.
The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.
Information:
Financial Forecast by Segment for the Full Year Ending March 31, 2024
(Millions of yen) | |||||
Fiscal 2023 | Fiscal 2023 | Variance in | Results for | ||
the Full Year | |||||
Previous | Revised | Amount | |||
ended March | |||||
Forecast (A) | Forecast (B) | (B-A) | |||
31, 2023 | |||||
Essential Chemicals | Sales revenue | 970,000 | 850,000 | -120,000 | 852,916 |
& Plastics | Core operating income | -7,000 | -75,000 | -68,000 | -34,197 |
Energy & Functional | Sales revenue | 370,000 | 320,000 | -50,000 | 342,460 |
Materials | Core operating income | 13,000 | 2,000 | -11,000 | 15,239 |
IT-related Chemicals | Sales revenue | 430,000 | 410,000 | -20,000 | 431,219 |
Core operating income | 38,000 | 33,000 | -5,000 | 47,601 | |
Health & Crop | Sales revenue | 610,000 | 610,000 | - | 598,390 |
Sciences | Core operating income | 62,000 | 40,000 | -22,000 | 57,277 |
Pharmaceuticals | Sales revenue | 400,000 | 420,000 | 20,000 | 584,873 |
Core operating income | -61,000 | -69,000 | -8,000 | 16,168 | |
Others / | Sales revenue | 120,000 | 90,000 | -30,000 | 85,425 |
Adjustments | Core operating income | -5,000 | -1,000 | 4,000 | -9,336 |
Total | Sales revenue | 2,900,000 | 2,700,000 | -200,000 | 2,895,283 |
Core operating income | 40,000 | -70,000 | -110,000 | 92,752 | |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Sumitomo Chemical Co. Ltd. published this content on 01 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 November 2023 06:04:43 UTC.